Symbols / PTGX $98.28 +1.58%
PTGX Chart
About
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.27B |
| Enterprise Value | 5.62B | Income | -130.15M | Sales | 46.02M |
| Book/sh | 9.82 | Cash/sh | 8.89 | Dividend Yield | — |
| Payout | 0.00% | Employees | 132 | IPO | — |
| P/E | — | Forward P/E | -168.07 | PEG | — |
| P/S | 136.28 | P/B | 10.01 | P/C | — |
| EV/EBITDA | -35.81 | EV/Sales | 122.05 | Quick Ratio | 12.59 |
| Current Ratio | 12.71 | Debt/Eq | 1.68 | LT Debt/Eq | — |
| EPS (ttm) | -2.05 | EPS next Y | -0.58 | EPS Growth | — |
| Revenue Growth | -95.60% | Earnings | 2026-05-06 | ROA | -13.99% |
| ROE | -20.18% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -6.77% | Profit Margin | -282.83% | Shs Outstand | 63.81M |
| Shs Float | 51.90M | Short Float | 15.32% | Short Ratio | 12.67 |
| Short Interest | — | 52W High | 99.31 | 52W Low | 39.60 |
| Beta | 2.24 | Avg Volume | 744.49K | Volume | 114.85K |
| Target Price | $107.83 | Recom | Strong_buy | Prev Close | $96.75 |
| Price | $98.28 | Change | 1.58% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$107.83
Mean price target
2. Current target
$97.32
Latest analyst target
3. DCF / Fair value
$29.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$97.32
Low
$95.00
High
$118.00
Mean
$107.83
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-03 | main | Goldman Sachs | Neutral → Neutral | $95 |
| 2026-02-26 | main | TD Cowen | Buy → Buy | $100 |
| 2026-02-26 | main | Barclays | Overweight → Overweight | $113 |
| 2026-02-26 | main | Citizens | Market Outperform → Market Outperform | $112 |
| 2026-02-02 | main | Jefferies | Buy → Buy | $118 |
| 2026-01-30 | main | HC Wainwright & Co. | Buy → Buy | $117 |
| 2026-01-05 | main | Truist Securities | Buy → Buy | $110 |
| 2025-12-17 | main | Barclays | Overweight → Overweight | $108 |
| 2025-12-08 | main | Citigroup | Buy → Buy | $115 |
| 2025-11-10 | main | Citigroup | Buy → Buy | $98 |
| 2025-11-07 | main | JP Morgan | Overweight → Overweight | $81 |
| 2025-11-07 | main | Barclays | Overweight → Overweight | $88 |
| 2025-11-07 | main | Citizens | Market Outperform → Market Outperform | $102 |
| 2025-10-28 | main | Truist Securities | Buy → Buy | $88 |
| 2025-10-28 | main | Wedbush | Outperform → Outperform | $86 |
| 2025-10-28 | reit | BTIG | Buy → Buy | $82 |
| 2025-10-17 | main | Citigroup | Buy → Buy | $96 |
| 2025-10-08 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-09-17 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-09-17 | init | Barclays | — → Overweight | $72 |
- Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's Why - MarketBeat ue, 17 Mar 2026 15
- Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift - Yahoo Finance Sat, 28 Feb 2026 08
- Protagonist Therapeutics, Inc. $PTGX Stock Holdings Lifted by Boxer Capital Management LLC - MarketBeat Sun, 15 Mar 2026 11
- Protagonist CEO lines up five healthcare investor events for March - Stock Titan ue, 24 Feb 2026 08
- Protagonist (PTGX) Stock Pre-Market (-6.4%): NDA Submission For Rusfertide Triggers Sell-The-News - Trefis ue, 06 Jan 2026 08
- Insider Sale: Director at $PTGX Sells 18,000 Shares | PTGX Stock News - Quiver Quantitative Wed, 18 Feb 2026 08
- Assessing Protagonist Therapeutics (PTGX) Valuation After Strong Recent Share Price Momentum - simplywall.st hu, 05 Mar 2026 08
- Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - The Motley Fool Wed, 25 Feb 2026 08
- Responsive Playbooks and the PTGX Inflection - Stock Traders Daily ue, 10 Mar 2026 00
- Is Protagonist Therapeutics (PTGX) Still Attractive After A 136% One Year Share Price Surge - simplywall.st Wed, 04 Mar 2026 08
- CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Yahoo Finance Wed, 25 Feb 2026 08
- Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Mangrove Partners IM LLC - MarketBeat Sat, 14 Mar 2026 11
- Protagonist Therapeutics (PTGX): Evaluating Valuation After a 65% Year-to-Date Share Price Surge - Yahoo Finance ue, 07 Oct 2025 07
- Protagonist Therapeutics, Inc. $PTGX Holdings Boosted by HighVista Strategies LLC - MarketBeat Mon, 16 Mar 2026 11
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat Mon, 16 Mar 2026 06
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 18000 | 1483560 | — | Sale at price 82.42 per share. | WILLIAMS LEWIS T | Director | — | 2026-02-17 00:00:00 | D |
| 1 | 18000 | 195120 | — | Conversion of Exercise of derivative security at price 10.84 per share. | WILLIAMS LEWIS T | Director | — | 2026-02-17 00:00:00 | D |
| 2 | 20000 | 1673600 | — | Sale at price 83.68 per share. | WADDILL WILLIAM D | Director | — | 2026-02-06 00:00:00 | D |
| 3 | 20000 | 166200 | — | Conversion of Exercise of derivative security at price 8.31 per share. | WADDILL WILLIAM D | Director | — | 2026-02-06 00:00:00 | D |
| 4 | 48273 | 4063743 | — | Sale at price 83.19 - 84.59 per share. | PATEL DINESH V | Chief Executive Officer | — | 2026-01-27 00:00:00 | D |
| 5 | 23151 | 1905305 | — | Sale at price 82.00 - 82.42 per share. | MOLINA ARTURO MD | Officer | — | 2026-01-27 00:00:00 | D |
| 6 | 46203 | 3841037 | — | Sale at price 83.13 - 83.14 per share. | ALI ASIF | Chief Financial Officer | — | 2026-01-27 00:00:00 | D |
| 7 | 28000 | 453080 | — | Conversion of Exercise of derivative security at price 12.17 - 19.19 per share. | ALI ASIF | Chief Financial Officer | — | 2026-01-27 00:00:00 | D |
| 8 | 48273 | 520631 | — | Conversion of Exercise of derivative security at price 4.21 - 21.58 per share. | PATEL DINESH V | Chief Executive Officer | — | 2026-01-27 00:00:00 | D |
| 9 | 10000 | 80400 | — | Conversion of Exercise of derivative security at price 8.04 per share. | MOLINA ARTURO MD | Officer | — | 2026-01-27 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.02 | 0.00 | 0.00 |
| NormalizedEBITDA | -156.85M | 253.67M | -92.67M | -130.34M |
| TotalUnusualItems | 0.00 | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -130.15M | 275.19M | -78.95M | -127.39M |
| ReconciledDepreciation | 1.28M | 826.00K | 977.00K | 1.03M |
| EBITDA | -156.85M | 253.67M | -92.67M | -130.34M |
| EBIT | -158.13M | 252.84M | -93.65M | -131.37M |
| NetInterestIncome | 28.79M | 26.32M | 14.90M | 4.06M |
| InterestExpense | 0.00 | 0.00 | ||
| InterestIncome | 28.79M | 26.32M | 14.90M | 4.06M |
| NormalizedIncome | -130.15M | 275.19M | -78.95M | -127.39M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -130.15M | 275.19M | -78.95M | -127.39M |
| TotalExpenses | 204.14M | 181.59M | 153.65M | 157.95M |
| TotalOperatingIncomeAsReported | -158.13M | 252.84M | -93.65M | -131.37M |
| DilutedAverageShares | 63.57M | 65.08M | 56.76M | 49.04M |
| BasicAverageShares | 63.57M | 61.57M | 56.76M | 49.04M |
| DilutedEPS | -2.05 | 4.23 | -1.39 | -2.60 |
| BasicEPS | -2.05 | 4.47 | -1.39 | -2.60 |
| DilutedNIAvailtoComStockholders | -130.15M | 275.19M | -78.95M | -127.39M |
| NetIncomeCommonStockholders | -130.15M | 275.19M | -78.95M | -127.39M |
| NetIncome | -130.15M | 275.19M | -78.95M | -127.39M |
| NetIncomeIncludingNoncontrollingInterests | -130.15M | 275.19M | -78.95M | -127.39M |
| NetIncomeContinuousOperations | -130.15M | 275.19M | -78.95M | -127.39M |
| TaxProvision | 838.00K | 4.22M | 0.00 | 0.00 |
| PretaxIncome | -129.31M | 279.41M | -78.95M | -127.39M |
| OtherIncomeExpense | 27.00K | 250.00K | -201.00K | -80.00K |
| OtherNonOperatingIncomeExpenses | 27.00K | 250.00K | -201.00K | -80.00K |
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 28.79M | 26.32M | 14.90M | 4.06M |
| InterestExpenseNonOperating | 0.00 | 0.00 | ||
| InterestIncomeNonOperating | 28.79M | 26.32M | 14.90M | 4.06M |
| OperatingIncome | -158.13M | 252.84M | -93.65M | -131.37M |
| OperatingExpense | 204.14M | 181.59M | 153.65M | 157.95M |
| ResearchAndDevelopment | 159.29M | 138.13M | 120.16M | 126.22M |
| SellingGeneralAndAdministration | 44.85M | 43.46M | 33.49M | 31.74M |
| GeneralAndAdministrativeExpense | 44.85M | 43.46M | 33.49M | 31.74M |
| OtherGandA | 44.85M | 43.46M | 33.49M | 31.74M |
| TotalRevenue | 46.02M | 434.43M | 60.00M | 26.58M |
| OperatingRevenue | 46.02M | 434.43M | 60.00M | 26.58M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 62.58M | 61.04M | 57.71M | 49.34M |
| ShareIssued | 62.58M | 61.04M | 57.71M | 49.34M |
| TotalDebt | 10.32M | 10.87M | 1.14M | 3.66M |
| TangibleBookValue | 614.71M | 675.29M | 336.68M | 215.61M |
| InvestedCapital | 614.71M | 675.29M | 336.68M | 215.61M |
| WorkingCapital | 532.13M | 544.24M | 334.30M | 211.90M |
| NetTangibleAssets | 614.71M | 675.29M | 336.68M | 215.61M |
| CapitalLeaseObligations | 10.32M | 10.87M | 1.14M | 3.66M |
| CommonStockEquity | 614.71M | 675.29M | 336.68M | 215.61M |
| TotalCapitalization | 614.71M | 675.29M | 336.68M | 215.61M |
| TotalEquityGrossMinorityInterest | 614.71M | 675.29M | 336.68M | 215.61M |
| StockholdersEquity | 614.71M | 675.29M | 336.68M | 215.61M |
| GainsLossesNotAffectingRetainedEarnings | 641.00K | -82.00K | -105.00K | -359.00K |
| OtherEquityAdjustments | 641.00K | -82.00K | -105.00K | -359.00K |
| RetainedEarnings | -470.67M | -340.52M | -615.71M | -536.75M |
| AdditionalPaidInCapital | 1.08B | 1.02B | 952.49M | 752.72M |
| CapitalStock | 1.00K | 1.00K | 1.00K | 0.00 |
| CommonStock | 1.00K | 1.00K | 1.00K | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 53.48M | 69.43M | 21.27M | 32.32M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 8.04M | 22.03M | 0.00 | 1.14M |
| NonCurrentDeferredLiabilities | 0.00 | 11.68M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 8.04M | 10.36M | 0.00 | 1.14M |
| LongTermCapitalLeaseObligation | 8.04M | 10.36M | 0.00 | 1.14M |
| CurrentLiabilities | 45.44M | 47.40M | 21.27M | 31.18M |
| CurrentDeferredLiabilities | 9.55M | 18.89M | 3.00K | 69.00K |
| CurrentDeferredRevenue | 9.55M | 18.89M | 3.00K | 69.00K |
| CurrentDebtAndCapitalLeaseObligation | 2.28M | 510.00K | 1.14M | 2.52M |
| CurrentCapitalLeaseObligation | 2.28M | 510.00K | 1.14M | 2.52M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 12.76M | 11.08M | 6.79M | 4.97M |
| PayablesAndAccruedExpenses | 20.84M | 16.92M | 13.34M | 23.63M |
| CurrentAccruedExpenses | 15.32M | 12.54M | 12.47M | 19.57M |
| Payables | 5.52M | 4.38M | 871.00K | 4.05M |
| OtherPayable | 185.00K | 74.00K | 99.00K | 415.00K |
| DuetoRelatedPartiesCurrent | 69.00K | 899.00K | ||
| TotalTaxPayable | 0.00 | 2.69M | 0.00 | |
| IncomeTaxPayable | 0.00 | 2.69M | 0.00 | |
| AccountsPayable | 5.34M | 1.61M | 772.00K | 3.64M |
| TotalAssets | 668.19M | 744.73M | 357.95M | 247.93M |
| TotalNonCurrentAssets | 90.61M | 153.08M | 2.37M | 4.85M |
| OtherNonCurrentAssets | 287.00K | 225.00K | 225.00K | 225.00K |
| InvestmentsAndAdvances | 78.64M | 140.25M | 0.00 | 0.00 |
| InvestmentinFinancialAssets | 0.00 | |||
| NetPPE | 11.69M | 12.61M | 2.15M | 4.63M |
| AccumulatedDepreciation | -8.31M | -7.04M | -6.23M | -5.25M |
| GrossPPE | 20.00M | 19.64M | 8.38M | 9.88M |
| Leases | 2.94M | 2.42M | 963.00K | 913.00K |
| OtherProperties | 15.58M | 15.77M | 6.28M | 7.88M |
| MachineryFurnitureEquipment | 1.49M | 1.45M | 1.14M | 1.09M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 577.57M | 591.64M | 355.58M | 243.08M |
| OtherCurrentAssets | 42.00K | 975.00K | ||
| RestrictedCash | 0.00 | |||
| PrepaidAssets | 5.71M | 4.24M | 3.63M | 5.67M |
| Receivables | 4.50M | 168.49M | 10.33M | 52.00K |
| OtherReceivables | 10.00K | 248.00K | 76.00K | 42.00K |
| DuefromRelatedPartiesCurrent | 121.00K | 165.00M | 10.00M | 10.00K |
| TaxesReceivable | 0.00 | 2.79M | ||
| AccruedInterestReceivable | 4.37M | 3.24M | 256.00K | |
| CashCashEquivalentsAndShortTermInvestments | 567.36M | 418.91M | 341.62M | 237.35M |
| OtherShortTermInvestments | 438.97M | 321.66M | 154.89M | 111.61M |
| CashAndCashEquivalents | 128.39M | 97.25M | 186.73M | 125.74M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 56.08M | 182.80M | -70.84M | -108.93M |
| RepaymentOfDebt | 0.00 | 0.00 | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 0.00 | 0.00 | 132.10M | 14.55M |
| CapitalExpenditure | -1.59M | -1.35M | -609.00K | -795.00K |
| InterestPaidSupplementalData | 3.69M | 1.53M | 0.00 | 0.00 |
| EndCashPosition | 128.68M | 97.47M | 186.95M | 125.97M |
| BeginningCashPosition | 97.47M | 186.95M | 125.97M | 123.89M |
| EffectOfExchangeRateChanges | 0.00 | 0.00 | -90.00K | -126.00K |
| ChangesInCash | 31.20M | -89.48M | 60.98M | 2.17M |
| FinancingCashFlow | 22.86M | 25.85M | 170.48M | 18.84M |
| CashFlowFromContinuingFinancingActivities | 22.86M | 25.85M | 170.48M | 18.84M |
| NetOtherFinancingCharges | -479.00K | -600.00K | -769.00K | -163.00K |
| ProceedsFromStockOptionExercised | 23.34M | 26.45M | 39.15M | 4.45M |
| NetCommonStockIssuance | 0.00 | 0.00 | 132.10M | 14.55M |
| CommonStockIssuance | 0.00 | 0.00 | 132.10M | 14.55M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | 0.00 | ||
| LongTermDebtPayments | 0.00 | 0.00 | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -49.33M | -299.48M | -39.26M | 91.47M |
| CashFlowFromContinuingInvestingActivities | -49.33M | -299.48M | -39.26M | 91.47M |
| NetInvestmentPurchaseAndSale | -47.74M | -298.13M | -38.65M | 92.26M |
| SaleOfInvestment | 498.84M | 323.57M | 152.40M | 307.14M |
| PurchaseOfInvestment | -546.59M | -621.70M | -191.04M | -214.87M |
| NetPPEPurchaseAndSale | -1.59M | -1.35M | -609.00K | -795.00K |
| PurchaseOfPPE | -1.59M | -1.35M | -609.00K | -795.00K |
| OperatingCashFlow | 57.67M | 184.15M | -70.24M | -108.14M |
| CashFlowFromContinuingOperatingActivities | 57.67M | 184.15M | -70.24M | -108.14M |
| ChangeInWorkingCapital | 146.21M | -122.61M | -19.51M | -7.77M |
| ChangeInOtherWorkingCapital | -21.02M | 30.57M | -1.60M | -12.88M |
| ChangeInOtherCurrentLiabilities | -903.00K | -2.23M | -2.74M | -2.66M |
| ChangeInPayablesAndAccruedExpense | 5.61M | 7.82M | -8.53M | -11.50M |
| ChangeInAccruedExpense | 4.58M | 4.29M | -5.60M | -12.71M |
| ChangeInPayable | 1.03M | 3.53M | -2.93M | 1.22M |
| ChangeInAccountPayable | 3.72M | 842.00K | -2.87M | 2.04M |
| ChangeInTaxPayable | -2.69M | 2.69M | 0.00 | 0.00 |
| ChangeInIncomeTaxPayable | -2.69M | 2.69M | 0.00 | 0.00 |
| ChangeInPrepaidAssets | -2.36M | -3.77M | 1.75M | 3.75M |
| ChangeInReceivables | 164.88M | -155.00M | -9.99M | 4.24M |
| OtherNonCashItems | 1.58M | 2.07M | 2.53M | 2.33M |
| StockBasedCompensation | 45.97M | 37.55M | 29.29M | 24.20M |
| AmortizationOfSecurities | -7.22M | -8.88M | -4.57M | -549.00K |
| DeferredTax | 0.00 | 0.00 | ||
| DeferredIncomeTax | 0.00 | 0.00 | ||
| DepreciationAmortizationDepletion | 1.28M | 826.00K | 977.00K | 1.03M |
| DepreciationAndAmortization | 1.28M | 826.00K | 977.00K | 1.03M |
| Depreciation | 1.28M | 826.00K | 977.00K | 1.03M |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -130.15M | 275.19M | -78.95M | -127.39M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PTGX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|